奥利弗·萨托尔与托马斯·A·霍普、热雷米·卡莱和沃尔夫冈·P·芬德勒就前列腺特异性膜抗原（PSMA）获得美国食品药品监督管理局（FDA）批准一事进行了交谈。 - Suppr

Suppr

超能文献

Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.

作者信息

Sartor Oliver, Hope Thomas A, Calais Jeremie, Fendler Wolfgang P

机构信息

Tulane University School of Medicine, New Orleans, Louisiana.

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

出版信息

J Nucl Med. 2021 Feb;62(2):146-148. doi: 10.2967/jnumed.120.261834.

DOI:10.2967/jnumed.120.261834

PMID:33468543

Abstract

摘要

相似文献

Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.

J Nucl Med. 2021 Feb;62(2):146-148. doi: 10.2967/jnumed.120.261834.

Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.

J Nucl Med. 2021 Feb;62(2):149-155. doi: 10.2967/jnumed.120.260455. Epub 2020 Dec 18.

FDA cGMP requirements for PET drugs.

J Nucl Med. 2011 May;52(5):16N.

Advantage of F-PSMA-1007 over Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1076-1077. doi: 10.1007/s00259-018-3952-0. Epub 2018 Feb 14.

PSMA PET in Prostate Cancer.

J Nucl Med. 2015 Aug;56(8):1131-2. doi: 10.2967/jnumed.115.157339. Epub 2015 May 14.

Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):195-196. doi: 10.1007/s00259-015-3236-x. Epub 2015 Oct 27.

⁶⁸Ga-PSMA imaging of metastatic breast cancer.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1482-3. doi: 10.1007/s00259-015-3066-x. Epub 2015 May 1.

(68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):394-6. doi: 10.1007/s00259-015-3212-5.

[(68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence].

Radiologe. 2015 Feb;55(2):89-91. doi: 10.1007/s00117-014-2792-6.

Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):193-194. doi: 10.1007/s00259-015-3235-y. Epub 2015 Oct 27.

引用本文的文献

Radiolabeled PSMA Inhibitors.

Cancers (Basel). 2021 Dec 13;13(24):6255. doi: 10.3390/cancers13246255.

PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.

J Nucl Med. 2022 Jan;63(1):76-80. doi: 10.2967/jnumed.121.262821. Epub 2021 Oct 7.

Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy.

Diagnostics (Basel). 2021 Mar 30;11(4):622. doi: 10.3390/diagnostics11040622.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.

J Nucl Med. 2021 Feb;62(2):146-148. doi: 10.2967/jnumed.120.261834.

Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.

J Nucl Med. 2021 Feb;62(2):149-155. doi: 10.2967/jnumed.120.260455. Epub 2020 Dec 18.

FDA cGMP requirements for PET drugs.

J Nucl Med. 2011 May;52(5):16N.

Advantage of F-PSMA-1007 over Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1076-1077. doi: 10.1007/s00259-018-3952-0. Epub 2018 Feb 14.

PSMA PET in Prostate Cancer.

J Nucl Med. 2015 Aug;56(8):1131-2. doi: 10.2967/jnumed.115.157339. Epub 2015 May 14.

Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):195-196. doi: 10.1007/s00259-015-3236-x. Epub 2015 Oct 27.

⁶⁸Ga-PSMA imaging of metastatic breast cancer.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1482-3. doi: 10.1007/s00259-015-3066-x. Epub 2015 May 1.

(68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):394-6. doi: 10.1007/s00259-015-3212-5.

[(68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence].

Radiologe. 2015 Feb;55(2):89-91. doi: 10.1007/s00117-014-2792-6.

Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):193-194. doi: 10.1007/s00259-015-3235-y. Epub 2015 Oct 27.

引用本文的文献

Radiolabeled PSMA Inhibitors.

Cancers (Basel). 2021 Dec 13;13(24):6255. doi: 10.3390/cancers13246255.

PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.

J Nucl Med. 2022 Jan;63(1):76-80. doi: 10.2967/jnumed.121.262821. Epub 2021 Oct 7.

Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy.

Diagnostics (Basel). 2021 Mar 30;11(4):622. doi: 10.3390/diagnostics11040622.